Press
Releases

October 7, 2025 Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases October 7, 2025 Jade Biosciences Announces $135 Million Private Placement September 2, 2025 Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy August 25, 2025 Jade Biosciences to Participate in Upcoming Conferences August 13, 2025 Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update July 8, 2025 Jade Biosciences to Participate in Two Upcoming Investor Conferences July 1, 2025 Jade Biosciences Appoints Brad Dahms as Chief Financial Officer June 9, 2025 Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy June 2, 2025 Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress May 14, 2025 Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update